Next Article in Journal
A Novel Homozygous Variation in the PANK2 Gene in Two Persian Siblings with Atypical Pantothenate Kinase Associated Neurodegeneration
Previous Article in Journal
Continuous Glucose Monitoring Can Disclose Glucose Fluctuation in Advanced Parkinsonian Syndromes
 
 
Neurology International is published by MDPI from Volume 12 Issue 3 (2020). Previous articles were published by another publisher in Open Access under a CC-BY licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Features of Drug-induced Parkinsonism

by
Nobuko Shiraiwa
1,*,
Akira Tamaoka
1 and
Norio Ohkoshi
1
1
Course of Neurology, Department of Health Sciences, Tsukuba University of Technology, Japan
2
Deparment of Neurology, Graduate School of Comprehensive Human Science, University of Tsukuba, Japan
*
Author to whom correspondence should be addressed.
Neurol. Int. 2018, 10(4), 7877; https://doi.org/10.4081/ni.2018.7877
Submission received: 19 September 2018 / Revised: 10 October 2018 / Accepted: 8 November 2018 / Published: 20 December 2018

Abstract

Drug-induced Parkinsonism is often reversible after withdrawal of the causative drug. Its clinical course, however, is not well understood, as the majority of cases are caused by drugs prescribed by departments outside of neurology. We reviewed 21 cases of drug-induced parkinsonism for several factors, including age, sex, causative drug and reason for prescription, department by which it was prescribed, and outcome. The age at onset ranged from 40 to 87 years, with an average Hoehn and Yahr Scale score of 4, indicating severe disability. Sulpiride was the most commonly observed causative drug (71.4%). All causative drugs were prescribed in non-neurological departments and over one half were prescribed in non-psychiatric departments; most were prescribed to treat depression or abdominal discomfort. Ten patients (48%) were previously diagnosed with a neuromuscular disease, including cerebrovascular diseases and Parkinson’s disease. Recovery was observed in 15 cases (71%) after withdrawal of the causative drug, but lingering symptoms were observed in the remaining cases. It is suggested that physicians should be more cautious of Parkinsonian side effects when prescribing such drugs.
Keywords: Drug-induced parkinsonism; sulpiride; Parkinson’s disease; malignant syndrome; oromandibular dyskinesia Drug-induced parkinsonism; sulpiride; Parkinson’s disease; malignant syndrome; oromandibular dyskinesia

Share and Cite

MDPI and ACS Style

Shiraiwa, N.; Tamaoka, A.; Ohkoshi, N. Clinical Features of Drug-induced Parkinsonism. Neurol. Int. 2018, 10, 7877. https://doi.org/10.4081/ni.2018.7877

AMA Style

Shiraiwa N, Tamaoka A, Ohkoshi N. Clinical Features of Drug-induced Parkinsonism. Neurology International. 2018; 10(4):7877. https://doi.org/10.4081/ni.2018.7877

Chicago/Turabian Style

Shiraiwa, Nobuko, Akira Tamaoka, and Norio Ohkoshi. 2018. "Clinical Features of Drug-induced Parkinsonism" Neurology International 10, no. 4: 7877. https://doi.org/10.4081/ni.2018.7877

APA Style

Shiraiwa, N., Tamaoka, A., & Ohkoshi, N. (2018). Clinical Features of Drug-induced Parkinsonism. Neurology International, 10(4), 7877. https://doi.org/10.4081/ni.2018.7877

Article Metrics

Back to TopTop